Trailhead Biosystems is a biotechnology company that develops human iPSC-derived cells for drug discovery and cell therapies.
Trailhead Biosystems has raised $20.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.
Trailhead Biosystems's investors include Propel(X), MAK Capital, Entrepreneurship & Innovation Clinic at Yale Law School.
Trailhead Biosystems is headquartered in Beachwood, United States.
Trailhead Biosystems is a biotechnology company that develops human iPSC-derived cells for drug discovery and cell therapies.
Trailhead Biosystems is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trailhead Biosystems — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/trailhead-biosystems. Accessed July 23, 2026.
VCBacked. (2026). Trailhead Biosystems — Funding & Investors. Retrieved July 23, 2026, from https://www.vcbacked.co/company/trailhead-biosystems
{{cite web |title=Trailhead Biosystems — Funding & Investors |url=https://www.vcbacked.co/company/trailhead-biosystems |website=VCBacked |access-date=July 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated